
Gene Therapy Stocks That Turn Science Into Sales: 7 Picks
A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.
Every article, report, and earnings note where CRSP appears.

A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.

Biotech’s sharp outperformance is real, but the rally is rewarding profitable franchises and identifiable catalysts rather than lifting the entire sector. The better opportunity is selective exposure to de-risked pipelines, not indiscriminate bets on biotech as technology’s replacement.

A softer July PCE report could revive duration, but the best rebound candidates are profitable, catalyst-backed biotechs rather than every cash-burning growth stock. If inflation keeps yields high, JPM and Goldman offer the more defensible earnings-supported trade.

Alex Green of The Oxford Club is pitching the “Millionaire-Maker Stock,” a Nobel-linked biotech story that we trace and test against the filings.

Alexander Green of The Oxford Club is promoting The Next Magnificent Seven. We trace the Apple, NVIDIA and AI claims to the companies behind the pitch.
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.

A countdown of 7 gene editing stocks, with the top pick revealed last.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate CRSP ReportCancel anytime